This article analyzes current problems associated with surgical and systemic treatment for hereditary breast and ovarian cancers (including those associated with BRCA1/2 gene mutations). We discuss the issues related to clinical course of multiple primary tumors and their sensitivity to cytostatic and targeted therapy.